LOX inhibition (through BAPN) not only reduced collagen crosslinking and fibronectin assembly but also increased drug penetration and re-sensitized tumors to doxorubicin treatment in breast cancer [346], and enhanced sensitivity to radiotherapy in prostate cancer [347]. This evidence concerns the gene LOX and breast carcinoma.